Please Scroll Down to See Forums Below 
Although 'drol can effect everybody different, I wouldn't say it is too bad unless you have a history of easily heightened liver enzymes or hepatotoxicity. I'm pretty sure that most on this thread probably do not have HIV, and in the follwing study, it didn't seem to effects those in the study with HIV too bad if kept under 100mg/d. Considering that most Adrol cycles by most on these boards are usually no longer than 5-8 weeks, with some liver ancillaries like Tyler's and Milk thistle thrown in, I wouldn't get too carried away with it causing problems....for most.
Keep in mind that this was a 16 week study, which is longer than even 'most' BB'ers here on these boards partake in, so that has to be taken into perspective. Besides for maybe a few drugs (Fina, etc...), nothing has been as versatile and works as good as good ol' bad boy anadrol for me!!!
Obviously, training was not included in the study, if any was even performed, but I found it interesting that a twice a day dosing of 50mg's (100mg's/day) was just as effective as the 150mg's/day regimine....with a lot less hepatotoxicity. Whether or not a <10 week protocol [or for most of us <5-6 weeks) would be less harsh on ALT, AST, and GGT levels would have been interesting to to find out. Hell, even 8% from the PLACEBO group had 5 X the normal elevated liver enzyme levels.
It would also be nice, although it will probably never happen, to see how liver enzymes are affected when used in conjunction with a product like r-ALA and/or Tyler's....maybe someday....
Hell, with most anabolics, you will not get jack-shit from not training, A-50 is simply powerful and amazing!!!
HIV Clin Trials. 2003 May-Jun;4(3):150-63. Related Articles, Links
"Oxymetholone for the Treatment of HIV-Wasting: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial in Eugonadal Men and Women."
Hengge UR, Stocks K, Faulkner S, Wiehler H, Lorenz C, Jentzen W, Hengge D, Ringham G.
Department of Dermatology, University of Dusseldorf, Dusseldorf, Germany.
Background: Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients due to various alterations in energy metabolism and endocrine regulation. Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of lean body mass (LBM), but these treatments have largely not been sufficiently studied in eugonadal individuals.
Method: A double-blind, randomized, placebo-controlled trial of 89 HIV-positive eugonadal women and men with wasting assigned to the anabolic steroid oxymetholone (50 mg bid or tid) or placebo for 16 weeks was performed. Body weight, bioimpedance measurements, quality of life parameters, and appetite were analyzed.
Results: Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the tid and bid groups, respectively (p <.05 for each treatment versus placebo), while individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass [BCM) increased in the oxymetholone bid group [3.8 +/- 0.4 kg; p <.0001) and in the oxymetholone tid group [2.1 +/- 0.6 kg; p <.005). Significant improvements were noted in appetite and food intake, increased wellbeing, and reduced weakness by self-examination. The most important adverse event was liver-associated toxicity. Overall, 43% of patients in the tid group, 25% of patients in the bid oxymetholone group, and 8% in the placebo group had a greater than 5 times baseline increase for ALT, AST, or gammaGT, while other adverse events were not increased over placebo.
Conclusion: Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The bid (100 mg/day) regimen appeared to be equally effective to the tid (150 mg/day) regimen in terms of weight gain, LBM, and BCM and was associated with less liver toxicity.
BMJ
Keep in mind that this was a 16 week study, which is longer than even 'most' BB'ers here on these boards partake in, so that has to be taken into perspective. Besides for maybe a few drugs (Fina, etc...), nothing has been as versatile and works as good as good ol' bad boy anadrol for me!!!
Obviously, training was not included in the study, if any was even performed, but I found it interesting that a twice a day dosing of 50mg's (100mg's/day) was just as effective as the 150mg's/day regimine....with a lot less hepatotoxicity. Whether or not a <10 week protocol [or for most of us <5-6 weeks) would be less harsh on ALT, AST, and GGT levels would have been interesting to to find out. Hell, even 8% from the PLACEBO group had 5 X the normal elevated liver enzyme levels.
It would also be nice, although it will probably never happen, to see how liver enzymes are affected when used in conjunction with a product like r-ALA and/or Tyler's....maybe someday....
Hell, with most anabolics, you will not get jack-shit from not training, A-50 is simply powerful and amazing!!!
HIV Clin Trials. 2003 May-Jun;4(3):150-63. Related Articles, Links
"Oxymetholone for the Treatment of HIV-Wasting: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial in Eugonadal Men and Women."
Hengge UR, Stocks K, Faulkner S, Wiehler H, Lorenz C, Jentzen W, Hengge D, Ringham G.
Department of Dermatology, University of Dusseldorf, Dusseldorf, Germany.
Background: Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients due to various alterations in energy metabolism and endocrine regulation. Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of lean body mass (LBM), but these treatments have largely not been sufficiently studied in eugonadal individuals.
Method: A double-blind, randomized, placebo-controlled trial of 89 HIV-positive eugonadal women and men with wasting assigned to the anabolic steroid oxymetholone (50 mg bid or tid) or placebo for 16 weeks was performed. Body weight, bioimpedance measurements, quality of life parameters, and appetite were analyzed.
Results: Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the tid and bid groups, respectively (p <.05 for each treatment versus placebo), while individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass [BCM) increased in the oxymetholone bid group [3.8 +/- 0.4 kg; p <.0001) and in the oxymetholone tid group [2.1 +/- 0.6 kg; p <.005). Significant improvements were noted in appetite and food intake, increased wellbeing, and reduced weakness by self-examination. The most important adverse event was liver-associated toxicity. Overall, 43% of patients in the tid group, 25% of patients in the bid oxymetholone group, and 8% in the placebo group had a greater than 5 times baseline increase for ALT, AST, or gammaGT, while other adverse events were not increased over placebo.
Conclusion: Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The bid (100 mg/day) regimen appeared to be equally effective to the tid (150 mg/day) regimen in terms of weight gain, LBM, and BCM and was associated with less liver toxicity.
BMJ
